Article View: be.science
Article #349Cancer - Press review (January 21, 2012) – Revue de presse (21 janvier 2012)
From: SciMedWeb
Date: Sat, 21 Jan 2012 10:46
Date: Sat, 21 Jan 2012 10:46
204 lines
10343 bytes
10343 bytes
Cancer – Press Review – Revue de Presse Every week on http://marclacroixcancerblog.blogspot.com Chaque semaine sur http://marclacroixcancerblog.blogspot.com Press review (January 21, 2012) – Revue de presse (21 janvier 2012) Melanoma drug's link to other skin cancers identified The recently approved drug vemurafenib (Zelboraf) has been hailed as a breakthrough in the treatment of melanoma, the deadliest form of skin cancer. But roughly one-quarter of patients who take the medication develop a troublesome side effect: secondary skin cancers called squamous cell carcinomas. By Madonna Behen. In USA Today http://yourlife.usatoday.com/health/healthcare/studies/story/2012-01-19/Melanoma-drugs-link-to-other-skin-cancers-identified/52666570/1 HRT link to breast cancer 'flawed' Women who use HRT should be reassured that the treatment may not increase the risk of breast cancer, experts said, as the original study which raised fears was 'fundamentally flawed'. By Rebecca Smith. In Telegraph.co.uk http://www.telegraph.co.uk/health/healthnews/9017783/HRT-link-to-breast-cancer-flawed.html Blood Test Shows Promise in Spotting Pancreatic Cancers Early Another study suggests a similar test for those at risk for esophageal tumors. By Amanda Gardner. In U.S. News & World Report http://health.usnews.com/health-news/family-health/cancer/articles/2012/01/18/blood-test-shows-promise-in-spotting-pancreatic-cancers-early Aspirin merits testing for prevention of cervical cancer in HIV- infected women Research conducted by NewYork-Presbyterian Hospital/Weill Cornell Medical Center global health investigators and cancer specialists in New York, Qatar and Haiti suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV- infected women. In Medical Xpress http://medicalxpress.com/news/2012-01-aspirin-merits-cervical-cancer-hiv-infected.html Drug Duo May Help Fight Aggressive Form of Breast Cancer Combining two drugs (lapatinib and trastuzumab) that target an aggressive type of breast cancer known as HER2-positive appears to work better than using either drug alone, researchers report. By Kathleen Doheny. In U.S. News & World Report http://health.usnews.com/health-news/managing-your-healthcare/cancer/articles/2012/01/17/drug-duo-may-help-fight-aggressive-form-of-breast-cancer Solving the mystery of an old diabetes drug that may reduce cancer risk Research opens exciting new avenues in cancer preventione. In EurekAlert. http://www.eurekalert.org/pub_releases/2012-01/mu-stm011812.php Scriptaid Revives Breast Cancer Treatment Receptivity A study by researchers from the Sbarro Institute for Cancer Research and Molecular Medicine, reveals that despite the effectiveness of endocrine therapy for breast cancer, responsiveness to the treatment depends on expression of estrogen receptors in breast cancer cells. However, Dr. Laura Giacinti, lead investigator of the study reports on a new molecule, Scriptaid, which revives receptivity to the treatment in breast cancer cell lines that previously tested negative for the expression of estrogen receptors. The study appears in the Journal of Cellular Physiology.. By Grace Rattue. In Medical News Today http://www.medicalnewstoday.com/articles/240479.php Some Breast Cancer Spread May Be Triggered By Targetable Protein, Study Shows Discovery Points to Possible New Target for Therapy. By Jeffrey Norris. In UCSF Today http://www.ucsf.edu/news/2012/01/11322/some-breast-cancer-spread-may-be-triggered-targetable-protein-study-shows Stem CellsCancer Patient Receives a Man-Made Windpipe Surgeons fashion stem cells from bone marrow into a functional trachea By Alice Park. In TIME http://healthland.time.com/2012/01/13/cancer-patient-receives-a-man-made-windpipe/ Informed Patient: Diagnostic Errors Highlight Need for Second Opinions For patients diagnosed with cancer and other serious diseases, a second opinion can make the difference between getting the right and the wrong care, today’s Informed Patient column reports.. By Laura Landro. In Wall Street Journal http://blogs.wsj.com/health/2012/01/17/informed-patient-diagnostic-errors-highlight-need-for-second-opinions/ Study reveals origins of esophageal cancer New understanding of fastest-rising solid tumor in US. In EurekAlert. http://www.eurekalert.org/pub_releases/2012-01/cumc-sro011312.php Metastasis of pancreatic cancer in action Ben Stanger, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology at the Perelman School of Medicine, University of Pennsylvania, and Andrew Rhim, MD, a Gastroenterology Fellow in the Stanger lab, discovered that pancreatic cancer cells in an animal model begin to spread before clinically obvious tumor tissue is detected. What's more, they showed that inflammation enhances cancer progression in part by facilitating a cellular transformation that leads to entry of cancer cells into the circulation. They report their findings this week in Cell. In EurekAlert. http://www.eurekalert.org/pub_releases/2012-01/uops-mop011312.php Un biomarqueur détecte précocement des cancers pancréatiques Un nouveau biomarqueur testé dans le dépistage du cancer du pancréas pourrait détecter pratiquement les deux tiers des patients au stade 1 dans le cas de l’adénocarcinome ductal. Par Béatrice Vuaille. Dans Le Quotidien du Médecin http://www.lequotidiendumedecin.fr/information/un-biomarqueur-detecte-precocement-des-cancers-pancreatiques Cancer de la prostate: la prise en charge évolue Une étude confirme l'inutilité du dépistage systématique voire du traitement. Par Anne Prigent. Dans Le Figaro http://sante.lefigaro.fr/actualite/2012/01/17/17000-cancer-prostate-prise-charge-evolue Canada : Le cancer gagne du terrain Le taux de prévalence sur cinq ans pour l'ensemble des cancers a augmenté de 2,1 % par année entre 1997 et 2008 au pays, montrent les données compilées par Statistique Canada, mais qui excluent toutefois celles provenant du Québec. Sur Radio-Canada.ca. http://www.radio-canada.ca/nouvelles/sante/2012/01/18/001-canada-cancer-prevalence.shtml Le côté noir du ruban rose La prochaine fois qu'on va me proposer d'acheter un vernis à ongles rose pour appuyer la recherche sur le cancer du sein, je vais y penser à deux fois. Ce vernis est peut-être cancérigène. Par Sophie Durocher. Dans Canoë http://fr.canoe.ca/divertissement/tele-medias/chroniques/sophie-durocher/2012/01/18/19260181-jdm.html Que faire des médicaments efficaces mais peu rentables? Le scandale des anticancéreux périmés vendus par la société Alkopharma, basée à Martigny, met au jour une question délicate: dans une logique de rentabilité, que faire des médicaments chers à la production mais rares sur le marché? Par Sandrine Perroud. Dans La Tribune de Genève http://www.tdg.ch/suisse/Que-faire-des-medicaments-efficaces-mais-peu-rentables-/story/17055345 Le cancer tue l'Afrique en silence Longtemps considéré comme une maladie affectant surtout les pays occidentaux, le cancer frappe de plus en plus les pays en développement et notamment l'Afrique, où il n'est pas assez combattu. Par Gilles Klein. Dans Atlantico http://www.atlantico.fr/decryptage/cancer-tue-afrique-en-silence-266680.html Thérapies ciblées contre le cancer : de plus en plus de tests Un traitement anticancéreux « unique » pour chaque patient ? Les tests moléculaires prédictifs se développent et permettent aujourd’hui de proposer de plus en plus de thérapies réellement ciblées. Dans Destination Santé http://www.destinationsante.com/Therapies-ciblees-contre-le-cancer-de-plus-en-plus-de-tests.html (Liban) Les spécialistes persistent et signent : pas de liens entre les prothèses mammaires défectueuses et le cancer du sein Le nombre des femmes au Liban concernées par les implants mammaires défectueux de la société française Poly implant prothèse (PIP) est limité. Quelque 150 implants ont été vendus par l’agent de la société PIP au Liban et la liste des médecins les ayant utilisés a été communiquée au ministère de la Santé, afin qu’il prenne les mesures nécessaires. Dans L’Orient-Le Jour http://www.lorientlejour.com/category/Liban/article/740920/Les_specialistes_persistent_et_signent+%3A_pas_de_liens_entre_les_protheses_mammaires_defectueuses_et_le_cancer_du_sein.html Cancer Blog – Marc Lacroix – Le Blogue du Cancer http://marclacroixcancerblog.blogspot.com Marc Lacroix – InTextoResearch – Baelen (01/2012)
Technical Details
Message-ID:
<e0cb16b0-6442-4cf8-8465-2d499cfd88e1@g27g2000yqa.googlegroups.com>Path:
arc1-ca.pugleaf.net!lh20ni207031pbb.0!nntp.google.com!news1.google.com!postnews.google.com!g27g2000yqa.googlegroups.com!not-for-mailShow Full Headers
Complete Article Headers
X-Google-Thread: f5500,a9bbd1579d627479,start
X-Google-NewGroupId: yes
X-Google-Attributes: gida254ea4a8d,domainid0,public,usenet
X-Google-Language: ENGLISH,CP1252
Received: by 10.68.199.73 with SMTP id ji9mr1177612pbc.5.1327143178365;
Sat, 21 Jan 2012 02:52:58 -0800 (PST)
Path: arc1-ca.pugleaf.net!lh20ni207031pbb.0!nntp.google.com!news1.google.com!postnews.google.com!g27g2000yqa.googlegroups.com!not-for-mail
From: SciMedWeb <scimedweb@mail.com>
Newsgroups: be.science
Subject: Cancer - Press review (January 21, 2012) – Revue de presse (21 janvier 2012)
Date: Sat, 21 Jan 2012 02:46:55 -0800 (PST)
Organization: http://groups.google.com
Lines: 204
Message-ID: <e0cb16b0-6442-4cf8-8465-2d499cfd88e1@g27g2000yqa.googlegroups.com>
NNTP-Posting-Host: 81.247.64.216
Mime-Version: 1.0
X-Trace: posting.google.com 1327143178 24730 127.0.0.1 (21 Jan 2012 10:52:58 GMT)
X-Complaints-To: groups-abuse@google.com
NNTP-Posting-Date: Sat, 21 Jan 2012 10:52:58 +0000 (UTC)
Complaints-To: groups-abuse@google.com
Injection-Info: g27g2000yqa.googlegroups.com; posting-host=81.247.64.216; posting-account=jR3pwAkAAABfF7uqn-zMzWqez-yhPWKE
User-Agent: G2/1.0
X-Google-Web-Client: true
X-Google-Header-Order: UHALERCNK
X-HTTP-UserAgent: Opera/9.80 (Windows NT 5.1; U; fr) Presto/2.10.229 Version/11.60,gzip(gfe)
Content-Type: text/plain; charset=windows-1252
Content-Transfer-Encoding: quoted-printable